RA Capital Management’s Acrivon Therapeutics ACRV Stock Holding History

RA Capital Management’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.8M	Buy	12,229,396 +3,888,888	+47%	+$6.61M	0.19%	61
2026 Q1	$11.6M	Hold	8,340,508	–	–	0.12%	72
2025 Q4	$20.1M	Hold	8,340,508	–	–	0.21%	49
2025 Q3	$15.1M	Hold	8,340,508	–	–	0.19%	48
2025 Q2	$9.93M	Hold	8,340,508	–	–	0.17%	46
2025 Q1	$16.9M	Hold	8,340,508	–	–	0.28%	48
2024 Q4	$50.2M	Hold	8,340,508	–	–	0.67%	31
2024 Q3	$58.4M	Hold	8,340,508	–	–	0.67%	33
2024 Q2	$48.4M	Buy	8,340,508 +3,530,000	+73%	+$28.4M	0.64%	39
2024 Q1	$34.4M	Hold	4,810,508	–	–	0.44%	49
2023 Q4	$23.7M	Hold	4,810,508	–	–	0.37%	44
2023 Q3	$46M	Hold	4,810,508	–	–	0.91%	33
2023 Q2	$62.3M	Hold	4,810,508	–	–	1.18%	26
2023 Q1	$61M	Hold	4,810,508	–	–	1.38%	25
2022 Q4	$55.4M	Buy	+4,810,508	New	+$61.1M	1.12%	26

Other funds holding ACRV

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RA Capital Management's ACRV Position: Q2 2026 in Review

RA Capital Management increased its Acrivon Therapeutics (ACRV) stake by 47% in Q2 2026, buying an estimated $6.61M and bringing the position to 12,229,396 shares worth $21.8M. The position accounts for 0.19% of the portfolio, ranked #61.

RA Capital Management first reported a position in ACRV in Q4 2022 and has held it in 15 quarters since. The position peaked at $62.3M in Q2 2023. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

RA Capital Management held 12,229,396 shares of Acrivon Therapeutics worth $21.8M as of Q2 2026.
RA Capital Management bought 3,888,888 Acrivon Therapeutics shares in Q2 2026, an estimated $6.61M.
Acrivon Therapeutics made up 0.19% of RA Capital Management's portfolio in Q2 2026, its #61 holding.
RA Capital Management first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 15 quarters since.
RA Capital Management's Acrivon Therapeutics position peaked at $62.3M in Q2 2023.
46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.